NCT04859543Completed
Pediatric Prospective Personalized Immune and Target Identification Trial
Prospective, Interventional Diagnostic, Multicenter, Non-treatment Clinical Study Identifying Specific Molecular Changes by Using Genomic Sequencing Technologies in Refractory/Recurrent or Very High-risk Pediatric CNS Tumors.
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 22 Apr 2021
- Start date
- 2 Feb 2021
- Primary completion date
- 10 Dec 2024
- Lead sponsor
- Masaryk University
- Diseases
- Childhood cancers
- NCT number
- NCT04859543
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 2 Feb 2021 to the primary completion date, 10 Dec 2024
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Other
- Pregnant and/or breastfeeding women, if applicable
- No intention to treat the patient.
Who the study is looking for
- Patient Informed consent form must be appropriately obtained under the applicable local and regulatory requirements. Each patient must sign a consent form prior the enrollment to document their willingness to participate.
- The subject is male or female, aged 1 - 19 years
- The subject must have a histologically proven recurrent/ refractory or very high-risk CNS tumors
- Patients must be in good overall physical condition, which allows tumor biopsy
- Patients must have a life expectancy of at least 3 months.
- Patients must have a tumor amenable to image-guided or direct vision biopsy and be willing and able to undergo a tumor biopsy and/or blood taking for molecular profiling.
- Patients must be accessible for follow-up.
Age in the registry: 1 year to 19 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Vienna Coordinator of this site? Confirm its status | Vienna | Austria | Unknown status |
| University Hospital Brno Coordinator of this site? Confirm its status | Brno | Czechia | Unknown status |
| Motol University Hospital Coordinator of this site? Confirm its status | Prague | Czechia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.